Retrospective analysis of amrubicin therapy for advanced or recurrent neuroendocrine carcinoma in our facility

Patients with advanced or recurrent neuroendocrine carcinoma (NEC) frequently treated with platinum-based chemotherapy for small cell lung carcinoma because of the clinicopathological similarities. However, further standard chemotherapies after the first-line treatment have not been sufficiently established in NEC. Amrubicin (AMR) is used in the salvage setting in several facilities.